Funder
Relmada Therapeutics Inc.
Relmada Therapeutics, Inc.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, et al. Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone. Mol Psychiatry. 2023. https://doi.org/10.1038/s41380-023-02353-z.
2. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther. 2002;303:557–62.
3. Lemberg K, Kontinen VK, Viljakka K, Kylänlahti I, Yli-Kauhaluoma J, Kalso E. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg. 2006;102:1768–74.
4. Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE. D-methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther. 1997;283:648–52.
5. Nair A. Alvimopan for post-operative ileus: What we should know? Acta Anaesthesiol. 2016;54:97–8.